Werbung
Deutsche Märkte öffnen in 3 Stunden 52 Minuten
  • Nikkei 225

    38.236,07
    -37,98 (-0,10%)
     
  • Dow Jones 30

    38.225,66
    +322,37 (+0,85%)
     
  • Bitcoin EUR

    55.645,84
    +2.082,62 (+3,89%)
     
  • CMC Crypto 200

    1.283,95
    +13,21 (+1,04%)
     
  • Nasdaq Compositive

    15.840,96
    +235,48 (+1,51%)
     
  • S&P 500

    5.064,20
    +45,81 (+0,91%)
     

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Zealand Pharma
Zealand Pharma

Company announcement – No. 23 / 2024

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Copenhagen, Denmark, April 19, 2024 Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.

WERBUNG

Please see the attached file(s).

# # #

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.

Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.

Contact:

Adam Lange
Investor Relations Officer
Zealand Pharma
Email: alange@zealandpharma.com

 

Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
Email: akrassowska@zealandpharma.com

Attachment